- Home
- SCPH vs CRVS Comparison
SCPH vs CRVS Comparison
Compare SCPH & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCPH
- CRVS
- Stock Information
- Founded
- SCPH 2013
- CRVS 2014
- Country
- SCPH United States
- CRVS United States
- Employees
- SCPH N/A
- CRVS N/A
- Industry
- SCPH Biotechnology: Pharmaceutical Preparations
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- SCPH Health Care
- CRVS Health Care
- Exchange
- SCPH Nasdaq
- CRVS Nasdaq
- Market Cap
- SCPH 173.6M
- CRVS 206.5M
- IPO Year
- SCPH 2017
- CRVS 2016
- Fundamental
- Price
- SCPH $2.44
- CRVS $4.43
- Analyst Decision
- SCPH Strong Buy
- CRVS Strong Buy
- Analyst Count
- SCPH 3
- CRVS 3
- Target Price
- SCPH $14.00
- CRVS $16.33
- AVG Volume (30 Days)
- SCPH 237.4K
- CRVS 1.4M
- Earning Date
- SCPH 05-16-2025
- CRVS 05-08-2025
- Dividend Yield
- SCPH N/A
- CRVS N/A
- EPS Growth
- SCPH N/A
- CRVS N/A
- EPS
- SCPH N/A
- CRVS N/A
- Revenue
- SCPH $36,332,000.00
- CRVS N/A
- Revenue This Year
- SCPH $109.32
- CRVS N/A
- Revenue Next Year
- SCPH $76.95
- CRVS N/A
- P/E Ratio
- SCPH N/A
- CRVS N/A
- Revenue Growth
- SCPH 167.28
- CRVS N/A
- 52 Week Low
- SCPH $1.94
- CRVS $1.75
- 52 Week High
- SCPH $5.65
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- SCPH 46.18
- CRVS 68.59
- Support Level
- SCPH $2.24
- CRVS $3.17
- Resistance Level
- SCPH $2.64
- CRVS $3.71
- Average True Range (ATR)
- SCPH 0.17
- CRVS 0.23
- MACD
- SCPH 0.01
- CRVS 0.08
- Stochastic Oscillator
- SCPH 38.46
- CRVS 95.47
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).